Synthetically engineered bacteria destroys superbugs

By Admin
Scientists in Singapore have engineered a ‘suicide bomber strain of bacteria which has the ability to destroy a common but deadly hospital superb...

Scientists in Singapore have engineered a ‘suicide bomber’ strain of bacteria which has the ability to destroy a common but deadly hospital superbug.

The researchers have taken a strain of E.Coli which is commonly present in the human gut and empowered it to recognise and kill the Pseudomonas aeruginosa bacteria.

Upon recognising the superbug the newly engineered bacteria produces a fatal toxin, before exploding to cover the entire area in the chemical.   

It is thought this is the first time a study has used synthetic biology to tackle an infectious diseases.

READ MORE FROM THE WDM CONTENT NETWORK:

To read the latest edition of Healthcare Global, click here

Lab tests of the bacteria found it destroyed 99 percent of targets and it is now hoped it could be used to tackle drug-resistant superbugs and infections.  

Pseudomonas aeruginosa is often found in hospitals and targets patients with weakened immune systems.

The superbug can be fatal as it causes infections in any bodily tissues that it can attach itself too, including the lungs, guts and the bladder.

The results of the research have been published in the Molecular Systems Biology journal.

Share

Featured Articles

Oracle Fusion Cloud Update Boost for Patients

Oracle Fusion Cloud SCM includes new Healthcare Marketplace solution to help hospitals & clinics optimise planning, automate processes and improve outcomes

WHO Tightens air Quality Guidelines as Pollution Kills 7mn

World Health Organisation tightens air pollution guidelines to safeguard health; COVID prompts WHO to redefine 'air-borne' as it relates to diseases

WHO Health Chatbot Built on 'Humanised' GenAI

World Health Organisation's GenAI digital health tool is built using ‘AI humanisation’ tech & designed to ease burden on health workers & educate on health

Costco Weight-Loss Drugs Move Highlights US AOM Growth

Medical Devices & Pharma

AstraZeneca Company Profile, as CEO Soriot Lands pay Deal

Medical Devices & Pharma

US Academic Medical Centres 'Struggling' says McKinsey

Hospitals